Insmed, Inc. (NASDAQ:INSM) Receives $205.77 Consensus PT from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have received a consensus rating of “Buy” from the twenty-four ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $204.6818.

A number of brokerages have commented on INSM. Royal Bank Of Canada boosted their price target on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday. Redburn Partners set a $263.00 price objective on shares of Insmed in a report on Thursday, December 4th. Guggenheim decreased their target price on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Wells Fargo & Company set a $195.00 target price on shares of Insmed in a report on Thursday, December 18th. Finally, UBS Group cut their price target on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th.

Insider Activity at Insmed

In other Insmed news, Director Leo Lee sold 75,000 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the transaction, the director directly owned 54,677 shares in the company, valued at approximately $10,711,224.30. This trade represents a 57.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the transaction, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. This represents a 5.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 296,799 shares of company stock valued at $54,296,286 over the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC grew its position in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares in the last quarter. Kingsview Wealth Management LLC lifted its position in shares of Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 60 shares in the last quarter. Choreo LLC boosted its stake in shares of Insmed by 2.9% in the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 65 shares during the last quarter. ORG Partners LLC grew its holdings in shares of Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 74 shares in the last quarter. Finally, Spire Wealth Management increased its position in shares of Insmed by 11.5% during the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 80 shares during the last quarter.

Insmed Stock Down 2.6%

INSM stock opened at $156.21 on Friday. The stock’s 50 day simple moving average is $184.40 and its 200 day simple moving average is $156.10. The company has a market cap of $33.31 billion, a P/E ratio of -25.24 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the prior year, the firm earned ($1.27) EPS. The company’s revenue was up 52.4% compared to the same quarter last year. On average, research analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.